© 1997 by European Society of Cardiology
Copyright © 1997, European Society of Cardiology
Endothelin-1 in the lungs of patients with pulmonary hypertension
aDepartment of Internal Medicine, CHU Pitié-Salpétrié, 43 Boulevard de l'Hôpital, 75013 Paris, France
bDepartment of Thoracic and Cardiovascular Surgery, CHU Pitié-Salpétrière, 43 Boulevard de l'Hôpital, 75013 Paris, France
cBiochemical Laboratory, CHU Pitié-Salpétrière, 43 Boulevard de l'Hôpital, 75013 Paris, France
dDepartment of Thoracic Surgery, Laennec Hospital, Paris, France
Background: Pulmonary hypertension (PH) is characterized by an increase in vascular tone and an abnormal proliferation of muscle cells in the walls of pulmonary arteries. Recent studies have found high plasma endothelin-1 (ET-1) concentrations in patients with PH. This study was conducted to assess whether elevated circulating ET-1 levels in PH really reflect excessive local pulmonary production. Methods: We prospectively studied ET-1 concentration in lung specimens from 6 control subjects and 13 patients with severe PH referred for lung or heart-lung transplantation (6 patients had primary PH and 7 PH secondary to congenital heart defect). Endothelin-like immunoreactivity (ET-LI) was measured in plasma and lung tissue, using a radioimmunoassay, after ET-1 extraction. Reverse-phase high-performance liquid chromatography was also performed. Results: Peripheral venous plasma ET-LI concentrations in patients with PH, whatever the cause, were greater than those in controls (10.7 ± 0.8 vs 5.3 ± 0.7 pg/ml; P < 0.0005). Pulmonary ET-LI was significantly higher in patients with PH, irrespective of its cause, than in controls (25.2 ± 5.1 vs 8.1 ± 1.1 pg/mg, P < 0.03). ET-LI pulmonary concentrations were slightly higher in Eisenmenger than in primary PH, but this was not significant (27.1 ± 8.6 vs 22.8 ± 5.4 pg/mg). Linear regression analysis indicated a small but significant correlation between ET-LI pulmonary concentrations and pulmonary vascular resistance in the patients with PH (r = 0.38; P = 0.047). In each case, HPLC separation of ET indicated that most of the immuno-reactivity was detected in the same fraction as ET-1. Conclusions: The striking increase in ET-1 pulmonary concentration provides new evidence that excessive local pulmonary ET-1 production may contribute to the vascular abnormalities of pulmonary hypertension.
KEYWORDS Pulmonary hypertension; Eisenmenger's syndrome; Endothelin-1; Human, lung
* Corresponding author. Tel. + 33-1 42 17 80 27; Fax + 33-1 42 17 80 33.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. Warwick, P. S. Thomas, and D. H. Yates Biomarkers in pulmonary hypertension Eur. Respir. J., August 1, 2008; 32(2): 503 - 512. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-H. Lee, D.-S. Lee, E.-K. Kim, K.-H. Choe, Y.-M. Oh, T.-S. Shim, S.-E. Kim, Y.-S. Lee, and S.-D. Lee Simvastatin Inhibits Cigarette Smoking-induced Emphysema and Pulmonary Hypertension in Rat Lungs Am. J. Respir. Crit. Care Med., October 15, 2005; 172(8): 987 - 993. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Migneault, S. Sauvageau, L. Villeneuve, E. Thorin, A. Fournier, N. Leblanc, and J. Dupuis Chronically Elevated Endothelin Levels Reduce Pulmonary Vascular Reactivity to Nitric Oxide Am. J. Respir. Crit. Care Med., March 1, 2005; 171(5): 506 - 513. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Galie, A. Manes, and A. Branzi The endothelin system in pulmonary arterial hypertension Cardiovasc Res, February 1, 2004; 61(2): 227 - 237. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Budhiraja, R. M. Tuder, and P. M. Hassoun Endothelial Dysfunction in Pulmonary Hypertension Circulation, January 20, 2004; 109(2): 159 - 165. [Full Text] [PDF]
|
|
|
|
 |
|
 F S Benjaminov, M Prentice, K W Sniderman, S Siu, P Liu, and F Wong Portopulmonary hypertension in decompensated cirrhosis with refractory ascites Gut, September 1, 2003; 52(9): 1355 - 1362. [Abstract] [Full Text]
|
|
|
|
 |
|
 X. Qing and I. M. Keith Targeted blocking of gene expression for CGRP receptors elevates pulmonary artery pressure in hypoxic rats Am J Physiol Lung Cell Mol Physiol, July 1, 2003; 285(1): L86 - L96. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Schulze-Neick, J. Li, J. A. Reader, L. Shekerdemian, A. N. Redington, and D. J. Penny The endothelin antagonist BQ123 reduces pulmonary vascular resistance after surgical intervention for congenital heart disease J. Thorac. Cardiovasc. Surg., September 1, 2002; 124(3): 435 - 441. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Johnson, A. Nohria, L. Garrett, J. C. Fang, J. Igo, M. Katai, P. Ganz, and M. A. Creager Contribution of endothelin to pulmonary vascular tone under normoxic and hypoxic conditions Am J Physiol Heart Circ Physiol, August 1, 2002; 283(2): H568 - H575. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. P. Jankov, R. Belcastro, E. Ovcina, J. Lee, H. Massaeli, S. J. Lye, and A. K. Tanswell Thromboxane A2 Receptors Mediate Pulmonary Hypertension in 60% Oxygen-exposed Newborn Rats by a Cyclooxygenase-independent Mechanism Am. J. Respir. Crit. Care Med., July 15, 2002; 166(2): 208 - 214. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G Espinosa, R Cervera, J Font, and R A Asherson The lung in the antiphospholipid syndrome Ann Rheum Dis, March 1, 2002; 61(3): 195 - 198. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ozaki, S. Kawashima, T. Yamashita, Y. Ohashi, Y. Rikitake, N. Inoue, K.-I. Hirata, Y. Hayashi, H. Itoh, and M. Yokoyama Reduced Hypoxic Pulmonary Vascular Remodeling by Nitric Oxide From the Endothelium Hypertension, February 1, 2001; 37(2): 322 - 327. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Pellicelli, G. Barbaro, F. Palmieri, E. Girardi, C. D'Ambrosio, A. Rianda, G. Barbarini, D. Frigiotti, M. C. Borgia, and N. Petrosillo Primary Pulmonary Hypertension in HIV Patients: A Systematic Review Angiology, January 1, 2001; 52(1): 31 - 41. [Abstract] [PDF]
|
|
|
|
|
|
S. Archer and S. Rich Primary Pulmonary Hypertension : A Vascular Biology and Translational Research "Work in Progress" Circulation, November 28, 2000; 102(22): 2781 - 2791. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Veyssier-Belot and P. Cacoub Role of endothelial and smooth muscle cells in the physiopathology and treatment management of pulmonary hypertension Cardiovasc Res, November 1, 1999; 44(2): 274 - 282. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B Prendergast, D E Newby, L E Wilson, D J Webb, and P S Mankad Early therapeutic experience with the endothelin antagonist BQ-123 in pulmonary hypertension after congenital heart surgery Heart, October 1, 1999; 82(4): 505 - 508. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Salvi {alpha}1-Adrenergic Hypothesis for Pulmonary Hypertension Chest, June 1, 1999; 115(6): 1708 - 1719. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Pellicelli, F. Palmieri, C. D'Ambrosio, A. Rianda, E. Boumis, E. Girardi, G. Antonucci, C. D'Amato, and M. C. Borgia Role of Human Immunodeficiency Virus in Primary Pulmonary Hypertension: Case Reports Angiology, December 1, 1998; 49(12): 1005 - 1011. [Abstract] [PDF]
|
|